Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincenzo Mazzaferro

Showing results (1-10 of 374) with videos related to

Pageof 38
Sort By:
Hepatology (Baltimore, Md.)|December 26, 2015
Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approachVincenzo Mazzaferro
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 31, 2007
Results of liver transplantation: with or without Milan criteria?Vincenzo Mazzaferro
Journal of Hepatology|July 9, 2010
Exploiting liver immunity for the prevention of hepatic metastasesLicia Rivoltini, Vincenzo Mazzaferro
Journal of Hepatology|November 13, 2013
Reply to: "Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue"Carlo Sposito, Vincenzo Mazzaferro
Hepatobiliary Surgery and Nutrition|January 18, 2019
The SIRveNIB and SARAH trials, radioembolization <i>vs</i>. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the futureCarlo Sposito, Vincenzo Mazzaferro
Best Practice & Research. Clinical Gastroenterology|September 28, 2014
Current challenges in liver transplantation for hepatocellular carcinomaSherrie Bhoori, Vincenzo Mazzaferro
Journal of Hepatology|April 13, 2025
Reply to: "Ruptured HCC: An entity in exile from the EASL Clinical Practice Guidelines!": Ruptured HCC: Not exiled, but navigating an evidence vacuumBruno Sangro, Vincenzo Mazzaferro
Journal of Hepatology|September 11, 2013
Reply to: "Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinoma"Carlo Sposito, Vincenzo Mazzaferro
The Lancet. Oncology|February 19, 2011
Principles for the best multidisciplinary meetingsVincenzo Mazzaferro, Pietro Majno
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|May 25, 2006
Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: questions, answers and demands for a common languagePietro Majno, Vincenzo Mazzaferro
Pageof 38

Showing results (1-10 of 374) with videos related to

Sort By:
Pageof 38
Hepatology (Baltimore, Md.)|December 26, 2015
Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approachVincenzo Mazzaferro
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 31, 2007
Results of liver transplantation: with or without Milan criteria?Vincenzo Mazzaferro
Journal of Hepatology|July 9, 2010
Exploiting liver immunity for the prevention of hepatic metastasesLicia Rivoltini, Vincenzo Mazzaferro
Journal of Hepatology|November 13, 2013
Reply to: "Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue"Carlo Sposito, Vincenzo Mazzaferro
Hepatobiliary Surgery and Nutrition|January 18, 2019
The SIRveNIB and SARAH trials, radioembolization <i>vs</i>. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the futureCarlo Sposito, Vincenzo Mazzaferro
Best Practice & Research. Clinical Gastroenterology|September 28, 2014
Current challenges in liver transplantation for hepatocellular carcinomaSherrie Bhoori, Vincenzo Mazzaferro
Journal of Hepatology|April 13, 2025
Reply to: "Ruptured HCC: An entity in exile from the EASL Clinical Practice Guidelines!": Ruptured HCC: Not exiled, but navigating an evidence vacuumBruno Sangro, Vincenzo Mazzaferro
Journal of Hepatology|September 11, 2013
Reply to: "Time is a crucial factor for the use of oncological treatment for post-transplantation recurrence of hepatocellular carcinoma"Carlo Sposito, Vincenzo Mazzaferro
The Lancet. Oncology|February 19, 2011
Principles for the best multidisciplinary meetingsVincenzo Mazzaferro, Pietro Majno
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|May 25, 2006
Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: questions, answers and demands for a common languagePietro Majno, Vincenzo Mazzaferro
Pageof 38